which factors may predict long-term outcomes with ropeginterferon alfa-2b for the treatment of pv?
Published 2 years ago • 1.5K plays • Length 2:40Download video MP4
Download video MP3
Similar videos
-
16:41
ropeginterferon alfa-2b for the treatment of low-risk patients with polycythemia vera
-
1:56
5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera
-
1:35
proud-pv/continuation-pv studies: benefits of ropeg ifn alfa-2b for the treatment of pv
-
11:19
should ropeginterferon become soc for all patients with low-risk pv?
-
3:15
what is the news about ropeginterferon?
-
1:49
current and future therapies for pv: ropeginterferon alfa-2b
-
5:17
determining the potential of ropeginterferon alfa-2b in polycythemia vera
-
2:40
safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
-
2:30
what’s new for the management of polycythemia vera?
-
1:29
ropeginterferon alfa-2b for polycythemia vera: impacts and considerations
-
10:32
10 facts mpn patients need to know about fda approval of ropegylated interferon alpha2b (besremi).
-
22:39
besremi (ropeginterferon alfa-2b-njft) injection for polycythemia vera (pv)
-
6:04
the need to improve diagnostic criteria in pv and other challenges in the field
-
2:05
ropeg in polycythemia vera: long-term proud-pv and conti-pv results
-
13:46
taking charge of my treatment: susan’s story
-
12:32
taking charge of my treatment: kevin's story
-
3:19
targeting jak2 v617f vaf in polycythemia vera & the efficacy of ropeginterferon alfa-2b
-
24:52
combination therapy with jak2 inhibitors in mpn
-
3:02
pilot study of ropeginterferon in early myelofibrosis